Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

ESMO Targeted Anticancer Therapies Congress 2022

Start date: 07 Mar 2022
End date: 08 Mar 2022
Location: Virtual

ESMO TAT, known as “The Home of Phase I in Oncology” offers participants a glimpse of the future of targeted anticancer therapies, focusing on promising new anticancer targets and agents, with a particular focus on those in early phase clinical development.

This is the place where stakeholders from academia and industry get the chance to discuss with clinicians, researchers, and regulators the global dissemination of knowledge and clinical research expertise in the field of innovative cancer therapeutics, to the benefit of cancer patients worldwide.

The 2022 edition of the congress unveiled the most exciting topics coming into the clinic at the moment, with scientific sessions bridging from new cellular therapies to target agents, from ADCs to protein degraders of molecular glues, and more.